Stonegate Capital Partners Updates Coverage on Cingulate Inc. Following FDA Complete Response Letter
Cingulate Inc. faces a CMC-driven resubmission process for CTx-1301 after FDA issues Complete Response Letter, but strong cash position and intact product thesis suggest timeline rather than viability is the key concern.
